GUFICBIO NSE filing

Certificate under SEBI Regulations for Quarter Ended September 30, 2025

The RealCase readLow impact Neutral

Gufic Biosciences Limited submits a certificate under SEBI Regulations for the quarter ended September 30, 2025, confirming the dematerialization of securities.

Why it matters

This is a standard compliance disclosure and is unlikely to have a significant impact on the company's stock price or operations.

The market read

The announcement is a routine compliance filing and does not contain any information that would be considered positive or negative.

* Gufic Biosciences Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. * The certificate confirms the dematerialization of securities for the quarter ended September 30, 2025. * MUFG Intime India Private Limited (formerly Link Intime India Private Limited), the Registrar and Share Transfer Agent (RTA), issued the certificate. * The RTA confirmed that securities received for dematerialization were processed and accepted/rejected to the depositories and that security certificates were mutilated and cancelled after due verification.

Filing to action

What to do with a filing like this

Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.

View original filing